Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

U.S. AntiCoagulants Market by Product (Betrixaban, Dabigatran, Edoxaban, Rivaroxaban, Eliquis) and by Application (Cardiovascular Diseases, Coronary Artery Diseases, Cardiac Arrhythmia, Myocardial Infarction, Heart Valve Replacement, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03638

Pages: NA

Charts: NA

Tables: NA

Anticoagulants are used to treat blood clotting. Blood clots are formed when platelets aggregate and protein binds to form a solid mass. However, blood clotting is essential to stop excessive bleeding in diseases such as hemophilia. Anticoagulants are used to treat clot formation by stopping the platelets aggregation.

The major factors that contribute to the growth of the U.S. Anticoagulants market include increase in prevalence of hematic diseases such as hemophilia, thalassemia, and others and rise in geriatric population.

Moreover, large number of clinical trials and innovative R&D approaches to develop advanced drugs drive the market growth. However, side effects such as, nose bleeding, bleeding gums and respiratory discomfort, and stringent regulation hinder the market. Increase in R&D activities in the field of pharmaceutical industries and rise in therapeutical applications are anticipated to provide new opportunities for the market.

The U.S. Anticoagulants market is segmented on the basis of product and application. Based on product, the market is divided into betrixaban, dabigatran, edoxaban, rivaroxaban, and eliquis. In terms of end user, it is classified into cardiovascular diseases, coronary artery diseases, cardiac arrhythmia, myocardial infarction, heart valve replacement, and others.

Key Benefits

  • The study provides an in-depth analysis of the U.S. Anticoagulants market with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to determine various products available in the market.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.

 Key Market Segments

  • By Product
    • Betrixaban
    • Dabigatran
    • Edoxaban
    • Rivaroxaban
    • Eliquis
  • By Application
    • Cardiovascular Diseases
    • Coronary Artery Diseases
    • Cardiac Arrhythmia
    • Myocardial Infarction
    • Heart Valve Replacement
    • Others

 
Key Market Players

  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Abbott
  • CoaguSense
  • Pfizer
  • Portola Pharmaceuticals
  • Daiichi Sankyo
  • Alere
  • C. H. Boehringer Sohn
  • Roche

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: U.S. ANTICOAGULANTS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Betrixaban

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dabigatran

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Edoxaban

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Rivaroxaban

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Eliquis

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: U.S. ANTICOAGULANTS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cardiovascular Diseases

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Coronary Artery Diseases

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cardiac Arrhythmia

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Myocardial Infarction

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Heart Valve Replacement

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Others

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: U.S. ANTICOAGULANTS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, product

        • 6.2.5.2 Market size and forecast, application

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, product

        • 6.2.6.2 Market size and forecast, application

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, product

        • 6.2.7.2 Market size and forecast, application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, product

        • 6.3.5.2 Market size and forecast, application

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, product

        • 6.3.6.2 Market size and forecast, application

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, product

        • 6.3.7.2 Market size and forecast, application

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, product

        • 6.3.8.2 Market size and forecast, application

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, product

        • 6.3.9.2 Market size and forecast, application

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, product

        • 6.3.10.2 Market size and forecast, application

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, product

        • 6.3.11.2 Market size and forecast, application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, product

        • 6.4.5.2 Market size and forecast, application

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, product

        • 6.4.6.2 Market size and forecast, application

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, product

        • 6.4.7.2 Market size and forecast, application

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, product

        • 6.4.8.2 Market size and forecast, application

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, product

        • 6.4.9.2 Market size and forecast, application

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, product

        • 6.4.10.2 Market size and forecast, application

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, product

        • 6.4.11.2 Market size and forecast, application

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, product

        • 6.4.12.2 Market size and forecast, application

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, product

        • 6.4.13.2 Market size and forecast, application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, product

        • 6.5.5.2 Market size and forecast, application

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, product

        • 6.5.6.2 Market size and forecast, application

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, product

        • 6.5.7.2 Market size and forecast, application

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, product

        • 6.5.8.2 Market size and forecast, application

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, product

        • 6.5.9.2 Market size and forecast, application

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, product

        • 6.5.10.2 Market size and forecast, application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Bristol-Myers Squibb

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Johnson And Johnson

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Pfizer

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Portola Pharmaceuticals

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Roche

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Abbott

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. CoaguSense

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Alere

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. C. H. Boehringer Sohn

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Daiichi Sankyo

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL U.S. ANTICOAGULANTS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. U.S. ANTICOAGULANTS MARKET FOR BETRIXABAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. U.S. ANTICOAGULANTS MARKET FOR DABIGATRAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. U.S. ANTICOAGULANTS MARKET FOR EDOXABAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. U.S. ANTICOAGULANTS MARKET FOR RIVAROXABAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. U.S. ANTICOAGULANTS MARKET FOR ELIQUIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL U.S. ANTICOAGULANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 8. U.S. ANTICOAGULANTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. U.S. ANTICOAGULANTS MARKET FOR CORONARY ARTERY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. U.S. ANTICOAGULANTS MARKET FOR CARDIAC ARRHYTHMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. U.S. ANTICOAGULANTS MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. U.S. ANTICOAGULANTS MARKET FOR HEART VALVE REPLACEMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. ANTICOAGULANTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. U.S. ANTICOAGULANTS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA U.S. ANTICOAGULANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 19. U.S. U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. CANADA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. CANADA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE U.S. ANTICOAGULANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. FRANCE U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. ITALY U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. ITALY U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. SPAIN U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. UK U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. UK U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. RUSSIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. REST OF EUROPE U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. ASIA-PACIFIC U.S. ANTICOAGULANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 44. CHINA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. CHINA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. JAPAN U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. INDIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. INDIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. SOUTH KOREA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. AUSTRALIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. THAILAND U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. MALAYSIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. INDONESIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. REST OF ASIA PACIFIC U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA U.S. ANTICOAGULANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. BRAZIL U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH AFRICA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. SAUDI ARABIA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. UAE U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. UAE U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. ARGENTINA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA U.S. ANTICOAGULANTS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. REST OF LAMEA U.S. ANTICOAGULANTS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 79. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 80. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 81. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 83. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 84. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 85. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 86. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. PFIZER: KEY EXECUTIVES
  • TABLE 88. PFIZER: COMPANY SNAPSHOT
  • TABLE 89. PFIZER: OPERATING SEGMENTS
  • TABLE 90. PFIZER: PRODUCT PORTFOLIO
  • TABLE 91. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. PORTOLA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 93. PORTOLA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 94. PORTOLA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 95. PORTOLA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 96. PORTOLA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. ROCHE: KEY EXECUTIVES
  • TABLE 98. ROCHE: COMPANY SNAPSHOT
  • TABLE 99. ROCHE: OPERATING SEGMENTS
  • TABLE 100. ROCHE: PRODUCT PORTFOLIO
  • TABLE 101. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. ABBOTT: KEY EXECUTIVES
  • TABLE 103. ABBOTT: COMPANY SNAPSHOT
  • TABLE 104. ABBOTT: OPERATING SEGMENTS
  • TABLE 105. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 106. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. COAGUSENSE: KEY EXECUTIVES
  • TABLE 108. COAGUSENSE: COMPANY SNAPSHOT
  • TABLE 109. COAGUSENSE: OPERATING SEGMENTS
  • TABLE 110. COAGUSENSE: PRODUCT PORTFOLIO
  • TABLE 111. COAGUSENSE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ALERE: KEY EXECUTIVES
  • TABLE 113. ALERE: COMPANY SNAPSHOT
  • TABLE 114. ALERE: OPERATING SEGMENTS
  • TABLE 115. ALERE: PRODUCT PORTFOLIO
  • TABLE 116. ALERE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. C. H. BOEHRINGER SOHN: KEY EXECUTIVES
  • TABLE 118. C. H. BOEHRINGER SOHN: COMPANY SNAPSHOT
  • TABLE 119. C. H. BOEHRINGER SOHN: OPERATING SEGMENTS
  • TABLE 120. C. H. BOEHRINGER SOHN: PRODUCT PORTFOLIO
  • TABLE 121. C. H. BOEHRINGER SOHN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. DAIICHI SANKYO: KEY EXECUTIVES
  • TABLE 123. DAIICHI SANKYO: COMPANY SNAPSHOT
  • TABLE 124. DAIICHI SANKYO: OPERATING SEGMENTS
  • TABLE 125. DAIICHI SANKYO: PRODUCT PORTFOLIO
  • TABLE 126. DAIICHI SANKYO: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL U.S. ANTICOAGULANTS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL U.S. ANTICOAGULANTS MARKET
  • FIGURE 3. SEGMENTATION U.S. ANTICOAGULANTS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN U.S. ANTICOAGULANTS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALU.S. ANTICOAGULANTS MARKET
  • FIGURE 11. U.S. ANTICOAGULANTS MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 12. U.S. ANTICOAGULANTS MARKET FOR BETRIXABAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. U.S. ANTICOAGULANTS MARKET FOR DABIGATRAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. U.S. ANTICOAGULANTS MARKET FOR EDOXABAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. U.S. ANTICOAGULANTS MARKET FOR RIVAROXABAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. U.S. ANTICOAGULANTS MARKET FOR ELIQUIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. U.S. ANTICOAGULANTS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 18. U.S. ANTICOAGULANTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. U.S. ANTICOAGULANTS MARKET FOR CORONARY ARTERY DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. U.S. ANTICOAGULANTS MARKET FOR CARDIAC ARRHYTHMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. U.S. ANTICOAGULANTS MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. U.S. ANTICOAGULANTS MARKET FOR HEART VALVE REPLACEMENT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. U.S. ANTICOAGULANTS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: U.S. ANTICOAGULANTS MARKET
  • FIGURE 30. TOP PLAYER POSITIONING,2022
  • FIGURE 31. BRISTOL-MYERS SQUIBB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. PORTOLA PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. PORTOLA PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. PORTOLA PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. COAGUSENSE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. COAGUSENSE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. COAGUSENSE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ALERE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ALERE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ALERE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. C. H. BOEHRINGER SOHN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. C. H. BOEHRINGER SOHN: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. C. H. BOEHRINGER SOHN: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. DAIICHI SANKYO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. DAIICHI SANKYO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. DAIICHI SANKYO: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
U.S. AntiCoagulants Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved